nach oben

Erschienen in:

01.05.2010

Human platelet alloantigens HPA-1, HPA-2, and HPA-3 polymorphisms associated with extent of severe coronary artery disease

verfasst von: Nesrine Abboud, Lakdhar Ghazouani, Sonia Ben-Hadj-Khalifa, Fatma Anabi, Faouzi Added, Ali Khalfallah, Brahim Nsiri, Wassim Y. Almawi, Touhami Mahjoub

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

The contribution of human platelet antigen (HPA)-1 (GPIIb/IIIa), HPA-2 (GPIb/IX), and HPA-3 (GPIIb/IIIa) polymorphisms to the risk of coronary artery disease (CAD) was investigated in 341 CAD patients and 316 matched control subjects. HPA genotyping was performed by PCR-SSP. Regression analysis was employed in assessing the contribution of these variants to CAD risk. The frequency of HPA-1b (P = .009) and HPA-3b (P = .004) alleles, and HPA-1a/1b (P = .045), HPA-1b/1b (P = .007), and HPA-3b/3b (P = .008) genotypes were higher in patients than control subjects. No significant association was demonstrated between the HPA variants and 1-, 2- and 3-vessel disease. HPA-1b/2a/3b (Pc = .021) and HPA-1b/2b/3a (Pc = .002) haplotypes were positively associated with CAD, thereby conferring a disease susceptibility nature to these haplotypes. Multivariate analysis confirmed the positive association of HPA-1b/2a/3b (aOR = 3.72; 95% CI = 1.49–9.28), and in addition identified HPA-1b/2a/3a (aOR = 2.49; 95% CI = 1.06–5.86) to be positively associated with CAD, after adjusting for a number of covariates. Our results demonstrate positive association of HPA variants and specific HPA-1/HPA-2/HPA-3 haplotypes with CAD in Tunisians.

Davies MJ (1995) Acute coronary thrombosis—the role of plaque disruption and its initiation and prevention. Eur Heart J 16:3–7PubMed

Fischer M, Broeckel U, Holmer S, Baessler A, Hengstenberg C, Mayer B, Erdmann J, Klein G, Riegger G, Jacob HJ, Schunkert H (2005) Distinct heritable patterns of angiographic coronary artery disease in families with myocardial infarction. Circulation 111:855–862CrossRefPubMed

Wang Q (2005) Molecular genetics of coronary artery disease. Curr Opin Cardiol 20:182–188CrossRefPubMed

Hackam DG, Anand SS (2003) Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 290:932–940CrossRefPubMed

Topol EJ (2005) The genomic basis of myocardial infarction. J Am Coll Cardiol 46:1456–1465CrossRefPubMed

Lentz SR (2005) Another lesson from the factor V Leiden mouse: thrombin generation drives arterial disease. Circulation 111:1733–1734CrossRefPubMed

Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J (2006) Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 367:651–658CrossRefPubMed

Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH (2000) Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 134:224–238

Ruggeri ZM (2002) Platelets in atherothrombosis. Nat Med 8:1227–1234CrossRefPubMed

10.

Santoso S (2003) Human platelet alloantigens. Transfus Apher Sci 28:227–236CrossRefPubMed

11.

Calvete JJ (1999) Platelet integrin GPIIb/IIIa: structure-function correlations. An update and lessons from other integrins. Proc Soc Exp Biol Med 222:29–38CrossRefPubMed

12.

Deckmyn H, Ulrichts H, Van De Walle G, Vanhoorelbeke K (2004) Platelet antigens and their function. Vox Sang 87(Suppl 2):105–111CrossRefPubMed

13.

Bray PF (2000) Platelet glycoprotein polymorphisms as risk factors for thrombosis. Curr Opin Hematol 7:284–289CrossRefPubMed

14.

Moshfegh K, Wuillemin WA, Redondo M, Lämmle B, Beer JH, Liechti-Gallati S, Meyer BJ (1999) Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case–control study. Lancet 353:351–354CrossRefPubMed

15.

Ulrichts H, Vanhoorelbeke K, Cauwenberghs S, Vauterin S, Kroll H, Santoso S, Deckmyn H (2003) von Willebrand Factor but not α-thrombin binding to platelet glycoprotein Ibα is influenced by the HPA-2 polymorphism. Arterioscler Thromb Vasc Biol 23:1302–1307CrossRefPubMed

16.

Halle L, Bigot A, Mulen-Imandy G, M’Bayo K, Jaeger G, Anani L, Martageix C, Bianchi F, Julien E, Kaplan C (2005) HPA polymorphism in sub-Saharan African populations: Beninese, Cameroonians, Congolese, and Pygmies. Tissue Antigens 65:295–298CrossRefPubMed

17.

Seo DH, Park SS, Kim DW, Furihata K, Ueno I, Han KS (1998) Gene frequencies of eight human platelet-specific antigens in Koreans. Transfus Med 8:129–132CrossRefPubMed

18.

Yan L, Zhu F, He J, Sandler SG (2006) Human platelet alloantigen systems in three Chinese ethnic populations. Immunohematology 22:6–10PubMed

19.

Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ (1996) A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334:1090–1094CrossRefPubMed

20.

Clemetson KJ (2001) Platelet receptors for adhesion and activation. Variability as a factor in susceptibility to cardiovascular diseases. Ital Heart J 2:816–818PubMed

21.

Corral J, Gonzalez-Conejero R, Vicente V (2004) Genetic determinants of platelet function in thromboembolic diseases. J Biol Regul Homeost Agents 18:166–171PubMed

22.

Meisel C, Lopez JA, Stangl K (2004) Role of platelet glycoprotein polymorphisms in cardiovascular diseases. Naunyn Schmiedebergs Arch Pharmacol 369:38–54CrossRefPubMed

23.

Böttiger C, Kastrati A, Koch W, Mehilli J, Seidl H, Schömig K, von Beckerath N, Schömig A (2000) HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost 83:559–562PubMed

24.

Hato T, Minamoto Y, Fukuyama T, Fujita S (1997) Polymorphism of HPA-1 through 6 on the platelet membrane glycoprotien receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am J Cardiol 80:1222–1224CrossRefPubMed

25.

Morita H, Kurihara H, Imai Y, Sugiyama T, Hamada C, Sakai E, Mori M, Nagai R (2001) Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and myocardial infarction in Japanese. An approach entailing melting curve analysis with specific fluorescent hybridization probes. Thromb Haemost 85:226–230PubMed

26.

Kluter H (1996) Rapid typing for human platelet antigens systems -1, -2, -3 and -5 by PCR amplification sequence-specific primers. Vox Sang 71:121–123CrossRefPubMed

27.

Hurd CM, Cavanagh G, Schuh A, Ouwehand WH, Metcalfe P (2002) Genotyping for platelet-specific antigens: techniques for the detection of single nucleotide polymorphisms. Vox Sang 83:1–12CrossRefPubMed

28.

Janssens A, Pardo MC, Steyerberg EW, van Duijn CM (2004) Revisiting the clinical validity of multiplex genetic testing in complex diseases. Am J Hum Genet 74:585–588CrossRefPubMed

29.

Yang QH, Khoury MJ, Friedman JM, Little J, Flanders WD (2005) How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol 34:1129–1137CrossRefPubMed

30.

Jones DC, Bunce M, Fuggle SV, Young NT, Marshall SE (2003) Human platelet alloantigens (HPAs): PCR-SSP genotyping of a UK population for 15 HPA alleles. Eur J Immunogenet 30:415–419CrossRefPubMed

31.

Kekomaki S, Hamalainen L, Kauppinen Makelin R, Palomaki H, Kaste M, Kontula K (1999) Genetic polymorphism of platelet glycoprotein IIIa in patients with acute myocardial infarction and acute ischaemic stroke. J Cardiovasc Risk 6:13–17PubMed

32.

Araújo F, Santos A, Araújo V, Henriques I, Monteiro F, Meireles E, Moreira I, David D, Maciel MJ, Cunha-Ribeiro LM (1999) Genetic risk factors in acute coronary disease. Haemostasis 29:212–218PubMed

33.

Lagercrantz J, Bergman M, Lundman P, Tornvall P, Hjemdahl P, Hamsten A, Eriksson P (2003) No evidence that the PLA1/PLA2 polymorphism of platelet glycoprotein IIIa is implicated in angiographically characterized coronary atherosclerosis and premature myocardial infarction. Blood Coagul Fibrinolysis 14:749–753CrossRefPubMed

34.

Anderson JL, King GJ, Bair TL, Elmer SP, Muhlestein JB, Habashi J, Carlquist JF (1999) Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease. J Am Coll Cardiol 33:727–733CrossRefPubMed

35.

Zotz RB, Winkelmann BR, Müller C, Boehm BO, März W, Scharf RE (2005) Association of polymorphisms of platelet membrane integrins alpha IIb(beta)3 (HPA-1b/Pl) and alpha2(beta)1 (alpha807TT) with premature myocardial infarction. J Thromb Haemost 3:1522–1529CrossRefPubMed

36.

Lekakis J, Bisti S, Tsougos E, Papathanassiou A, Dagres N, Ikonomidis I, Soteriadou E, Tselepis AD, Goudevenos J, Kremastinos DT (2008) Platelet glycoprotein IIb HPA-3 polymorphism and acute coronary syndromes. Int J Cardiol 127:46–50CrossRefPubMed

37.

Park S, Park HY, Park C, Ko YG, Im EK, Jo I, Shin C, Lee JB, Shim WH, Cho SY, Jang Y (2004) Association of the gene polymorphisms of platelet glycoprotein Ia and IIb/IIIa with myocardial infarction and extent of coronary artery disease in the Korean population. Yonsei Med J 45:428–434PubMed

38.

Li YH, Chen JH, Tsai WC, Chao TH, Guo HR, Tsai LM, Wu HL, Shi GY (2002) Synergistic effect of thrombomodulin promoter -33G/A polymorphism and smoking on the onset of acute myocardial infarction. Thromb Haemost 87:86–91PubMed

39.

Voetsch B, Damasceno BP, Camargo EC, Massaro A, Bacheschi LA, Scaff M, Annichino-Bizzacchi JM, Arruda VR (2000) Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 83:229–233PubMed

40.

Charakida M, Tousoulis D, Stefanadis C, Toutouzas P (2003) The impact of platelet glycoprotein IIIa and Ia polymorphisms in cardiovascular thrombotic disease. Ital Heart J 4:17–22PubMed

41.

Bojesen SE, Juul K, Schnohr P, Tybjaerg-Hansen A, Nordestgaard BG, Copenhagen City Heart Study (2003) Platelet glycoprotein IIb/IIIa Pl(A2)/Pl(A2) homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: the Copenhagen City Heart Study. J Am Coll Cardiol 42:661–667CrossRefPubMed

42.

Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C (1997) Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke 28:1392–1395PubMed

Titel: Human platelet alloantigens HPA-1, HPA-2, and HPA-3 polymorphisms associated with extent of severe coronary artery disease
verfasst von: Nesrine Abboud
Lakdhar Ghazouani
Sonia Ben-Hadj-Khalifa
Fatma Anabi
Faouzi Added
Ali Khalfallah
Brahim Nsiri
Wassim Y. Almawi
Touhami Mahjoub
Publikationsdatum: 01.05.2010
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 4/2010
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-009-0368-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Myocardial infarction due to late stent thrombosis following epileptic convulsive seizures

Relationship between 24-h air pollution, emergency department admission and diagnosis of acute coronary syndrome

Severe bleeding secondary to misuse of fondaparinux: a case report

Fructose-1,6-bisphosphate inhibits in vitro and ex vivo platelet aggregation induced by ADP and ameliorates coagulation alterations in experimental sepsis in rats

Comparative effects of cilostazol and aspirin on the impairment of endothelium-dependent cerebral vasodilation caused by acute cigarette smoking in rats